GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance. Read why LXRX stock ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a ...

With rates of juvenile type 2 diabetes rocketing in the US, doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years. Eli Lilly and Boehringer ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with a lower risk for incidental Parkinson disease among older adults with type 2 diabetes.

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

TheracosBio and BAMCO Africa, Inc. today announced they have partnered to bring BRENZAVVY® (bexagliflozin), an FDA-approved ...

Renee Rucinsky, DVM, DABVP, discussed insulin therapy and SGLT2 inhibitors in her lecture at the Fetch dvm360 conference in ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...